Efficacy of venlafaxine and placebo during long‐term treatment of depression: a pooled analysis of relapse rates

No abstract is available for this paper.

• Publication year

  1996

• Venue

  International Clinical Psychopharmacology

• Publication date

  1996-06-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1097/00004850-199606000-00008PMID 8803651
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia.

  1995cited by this paper
• A comparison of venlafaxine, trazodone, and placebo in major depression.

  1994cited by this paper
• Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression

  1993cited by this paper
• A 24‐week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression

  1993cited by this paper
• Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study.

  1993cited by this paper
• Citalopram 20 mg, Citalo ram 40 mg and Placebo in the Prevention of Relapse of Major Depression

  1992cited by this paper
• Pattern of recurrence of illness after recovery from an episode of major depression: a prospective study.

  1992cited by this paper
• Sertraline in the Prevention of Depression

  1992cited by this paper
• Venlafaxine in depressed outpatients.

  1991cited by this paper
• The Influence of Different Relapse Criteria on the Assessment of Long‐Term Efficacy of Sertraline

  1991cited by this paper
• Methodologic issues in maintenance therapy clinical trials.

  1991cited by this paper
• Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence.

  1991cited by this paper
• A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression.

  1991cited by this paper
• Prophylactic efficacy of maprotiline on unipolar depression relapse.

  1991cited by this paper
• Placebo‐Controlled Trial of Venlafaxine for the Treatment of Major Depression

  1991cited by this paper
• Long-term treatment of depression.

  1991cited by this paper
• Three-year outcomes for maintenance therapies in recurrent depression.

  1990cited by this paper
• The Prophylactic Efficacy of Fluoxetine in Unipolar Depression

  1988cited by this paper
• Continuation drug therapy for major depressive episodes: how long should it be maintained?

  1986cited by this paper
• Phenelzine for chronic depression: a study of continuation treatment.

  1986cited by this paper
• Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative.

  1986cited by this paper
• Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination.

  1984cited by this paper
• Continuation therapy with lithium and amitriptyline in unipolar depressive illness: a randomized, double-blind, controlled trial

  1984cited by this paper
• The efficacy of zimeldine in preventing depressive episodes in recurrent major depressive disorders — a double‐blind placebo‐controlled study

  1983cited by this paper
• Predictors of relapse in major depressive disorder.

  1983cited by this paper
• Relapse in major depressive disorder: analysis with the life table.

  1982cited by this paper
• Recurrence of depression after discontinuation of long-term amitriptyline treatment.

  1982cited by this paper
• Maintenance therapy with amitriptyline: a controlled trial.

  1980cited by this paper
• Major affective disorder as a recurrent illness: a critical review.

  1979cited by this paper
• A New Depression Scale Designed to be Sensitive to Change

  1979cited by this paper
• Continuation Therapy with Amitriptyline in Depression

  1978cited by this paper
• An evaluation of continuation therapy with tricyclic antidepressants in depressive illness

  1973cited by this paper
• A RATING SCALE FOR DEPRESSION

  1960cited by this paper

• POETREE: Interpretable Policy Learning with Adaptive Decision Trees

  2022cites this paper
• Trazodone and Depression

  2021cites this paper
• EnBrace HR for Depression Treatment and Prevention in Women Trying to Conceive and Early Pregnancy

  2019cites this paper
• Differing antidepressant maintenance methodologies.

  2017cites this paper
• An Analysis of Relapse Rates and Predictors of Relapse in 2 Randomized, Placebo-Controlled Trials of Desvenlafaxine for Major Depressive Disorder.

  2015cites this paper
• Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials

  2015cites this paper
• Desvenlafaxine for the treatment of major depressive disorder

  2014cites this paper
• Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder:a randomized controlled trial.

  2013cites this paper
• A case study of pooled-studies publications indicated potential for both valuable information and bias.

  2013cites this paper
• Serotonin noradrenaline reuptake inhibitors

  2012cites this paper
• A 10-month, open-label evaluation of desvenlafaxine in outpatients with major depressive disorder.

  2011cites this paper
• Drug Class Review: Second-Generation Antidepressants

  2011cites this paper
• Blue Again: Perturbational Effects of Antidepressants Suggest Monoaminergic Homeostasis in Major Depression

  2011influential citation
• Venlafaxine and Desvenlafaxine, Selective Norepinephrine and Serotonin Reuptake Inhibitors to Treat Major Depressive Disorder

  2010cites this paper
• Desvenlafaxine for the Prevention of Relapse in Major Depressive Disorder: Results of a Randomized Trial

  2010cites this paper
• Limitations of contemporary antidepressants: tolerability.

  2007cites this paper
• Impact of Study Design on the Results of Continuation Studies of Antidepressants

  2007cites this paper
• Drug treatment of depression in the 2000s: an overview of achievements in the last 10 years and future possibilities

  2006cites this paper
• Preventing Relapse and Recurrence of Depression: A Brief Review of Therapeutic Options

  2006cites this paper
• Melancholia: The Diagnosis, Pathophysiology and Treatment of Depressive Illness

  2006cites this paper
• The importance of long-term tolerability in achieving recovery

  2006cites this paper
• Maintenance treatment of major depression in old age.

  2006cites this paper
• Zásady dlouhodobé léčby deprese

  2005influential citation
• Combined effects of venlafaxine, nicotine replacement, and brief counseling on smoking cessation.

  2005cites this paper
• Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo

  2005influential citation
• Remission versus response: the new gold standard of antidepressant care.

  2004cites this paper
• Venlafaxine versus placebo in the preventive treatment of recurrent major depression.

  2004cites this paper
• Extended-release venlafaxine in relapse prevention for patients with major depressive disorder.

  2004cites this paper
• Natural course and placebo response in short-term, placebo-controlled studies in major depression: a meta-analysis of published and non-published studies.

  2004cites this paper
• Natural Course and Placebo Response in Short-Term, Placebo-Controlled Studies in Major Depression: A Meta-Analysis of Published and Non-published Studies

  2004cites this paper
• Duloxetine in the long-term treatment of major depressive disorder.

  2003cites this paper
• Dual Action Antidepressants and Some Important Considerations

  2003cites this paper
• The new generation of antidepressants.

  2003cites this paper
• Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond.

  2003cites this paper
• Escitalopram: a pharmacoeconomic review of its use in depression.

  2003cites this paper
• Venlafaxin ist kein SSRI, sondern ein SNRI, und das ist relevant

  2003influential citation
• Treatment of Recurrent Depression

  2003cites this paper
• Comparison of Behavioural Effects of Venlafaxine and Imipramine in Rats

  2003cites this paper
• A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor

  2003cites this paper
• The impact of treatment-resistant depression on health care utilization and costs.

  2002cites this paper
• Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes.

  2002cites this paper
• Efficacy of continuation treatment with hypericum perforatum in depression.

  2002cites this paper
• Global Benefit-risk Evaluation of Antidepressant Action: Comparison of Pooled Data for Venlafaxine, SSRIs, and Placebo

  2002cites this paper
• SNRIs: mechanism of action and clinical features

  2002cites this paper
• Optimizing outcomes in depression: focus on antidepressant compliance

  2002influential citation
• Maintenance treatment in depression: the role of pharmacological and psychological treatment

  2002cites this paper
• Introduction of escitalopram, a new SSRI in Finland: comparison of cost-effectiveness between the other SSRIs and SNRI for the treatment of depression and estimation of the budgetary impact

  2002cites this paper
• Fluoxetine Fluoxetine v. placebo in prevention of relapse placebo in prevention of relapse in post-traumatic stress disorder in post-traumatic stress disorder

  2002cites this paper
• Serotonin-Noradrenalin-selektive Antidepressiva (SNRI/NaSSA)

  2002cites this paper
• Efficacy of 17 β-Estradiol on Depression : Is Estrogen Deficiency Really Necessary ?

  2002cites this paper
• Efficacy of 17beta-estradiol on depression: is estrogen deficiency really necessary?

  2002cites this paper
• Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder

  2002cites this paper
• Alte und neue Antidepressiva

  2001cites this paper
• Optimizing pharmacotherapy of generalized anxiety disorder to achieve remission.

  2001cites this paper
• Clinician perspective on achieving and maintaining remission in depression.

  2001cites this paper
• Relapse and recurrence prevention in major depression: a critical review of placebo-controlled efficacy studies with special emphasis on methodological issues

  2001cites this paper
• Steps Following Attainment of Remission: Discontinuation of Antidepressant Therapy.

  2001influential citation
• Suicide risk in placebo-controlled studies of major depression.

  2001cites this paper
• Third-Generation Antidepressants

  2001cites this paper
• Unmet needs in the pharmacological management of depression

  2001cites this paper
• Sustained Response to Open-Label Venlafaxine in Drug-Resistant Major Depression

  2001cites this paper
• SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression.

  2000cites this paper
• Antidepressant efficacy of venlafaxine

  2000cites this paper
• Redefining antidepressant efficacy toward long-term recovery.

  1999cites this paper
• Extended antidepressant maintenance and discontinuation syndromes

  1998influential citation
• Absolute Bioavailability and Electroencephalographic Effects of Conventional and Extended‐Release Formulations of Venlafaxine in Healthy Subjects

  1998cites this paper
• Current awareness in human psychopharmacology

  1996cites this paper